Amgen and AstraZeneca have announced positive top-line results from the phase 3 trial of Tezspire (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).
Tezspire demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing). The safety profile of Tezspire was generally consistent with its approved indications.
EoE is a chronic and progressive epithelial-driven inflammatory disorder of the oesophagus affecting more than 470,000 people in the US, with the prevalence increasing five-fold since 2009.Â
Oesophageal inflammation can lead to dysphagia, food impaction and oesophageal narrowing. For patients, the risk of food moving slowly or becoming stuck can make daily meals difficult and stressful.3 Nearly half of patients, including adolescents, do not achieve adequate disease control with current first-line treatments, which include dietary restriction, swallowed topical corticosteroids and proton pump inhibitors.
